| Literature DB >> 26412308 |
Ashraf Hamarneh1, Vivek Sivaraman1, Heerajnarain Bulluck1, Hilary Shanahan2, Bonnie Kyle2, Manish Ramlall1, Robin Chung1, Claire Jarvis2, Maria Xenou2, Cono Ariti3, Roger Cordery1, Derek M Yellon1,4, Derek J Hausenloy1,4,5,6.
Abstract
Remote ischemic conditioning (RIC) using transient limb ischemia/reperfusion has been reported to reduce perioperative myocardial injury in patients undergoing coronary artery bypass grafting and/or valve surgery. The role of intravenous glyceryl trinitrate (GTN) therapy administered during cardiac surgery as a cardioprotective agent and whether it interferes with RIC cardioprotection is not clear and is investigated in the ERIC-GTN trial ( http://www.clinicaltrials.gov: NCT01864252). The ERIC-GTN trial is a single-site, double-blind, randomized, placebo-controlled study. Consenting adult patients (age > 18 years) undergoing elective coronary artery bypass grafting ± valve surgery with blood cardioplegia will be eligible for inclusion. Two hundred sixty patients will be randomized to 1 of 4 treatment groups following anesthetic induction: (1) RIC alone, a RIC protocol comprising three 5-minute cycles of simultaneous upper-arm and thigh cuff inflation/deflation followed by an intravenous (IV) placebo infusion; (2) GTN alone, a simulated sham RIC protocol followed by an IV GTN infusion; (3) RIC + GTN, a RIC protocol followed by an IV GTN infusion; and (4) neither RIC nor GTN, a sham RIC protocol followed by IV placebo infusion. The primary endpoint will be perioperative myocardial injury as quantified by the 72-hour area-under-the-curve serum high-sensitivity troponin T. The ERIC-GTN trial will determine whether intraoperative GTN therapy is cardioprotective during cardiac surgery and whether it affects RIC cardioprotection.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26412308 PMCID: PMC6490705 DOI: 10.1002/clc.22445
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882